Which drug should we use for stroke prevention in atrial fibrillation?

Purpose of review Oral anticoagulation (OAC) remains the mainstay for prevention of ischaemic stroke in atrial fibrillation. This article reviews the latest evidence and development of new oral anticoagulants for the prevention of ischaemic stroke, as well as bleeding risk assessment, mitigation and management. Recent findings Decision-making for stroke prevention has evolved towards the initial identification of ‘low-risk’ patients who do not need any antithrombotic therapy. Subsequent to this step, patients with at least 1 stroke risk factor can be offered effective stroke prevention, which is OAC. There is increased morbidity and mortality amongst warfarin users, if time in therapeutic range is poor. New oral anticoagulants (such as dabigatran, rivaroxaban, apixaban and edoxaban) offer relative efficacy, safety and convenience compared to warfarin, in relation to stroke prevention in atrial fibrillation. Bleeding risk can be assessed by HAS-BLED score, whereas the new SAMe-TT2R2 score can predict the patient's suitability for vitamin K antagonists. Summary The landscape for stroke prevention in atrial fibrillation has greatly changed. It is no longer a question of ‘if we treat’ but more of ‘how to treat’, as the presence of one or more stroke risk factors in atrial fibrillation confers a risk of fatal and devastating strokes. OAC use, whether as well controlled vitamin K antagonists or nonvitamin K antagonists oral anticoagulant, will reduce the burden of stroke in atrial fibrillation.

[1]  G. Lip,et al.  Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. , 2014, Chest.

[2]  S. Suissa,et al.  Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. , 2014, European heart journal.

[3]  E. Lang,et al.  The need to clot: a review of current management strategies for adverse bleeding events with new oral anticoagulants. , 2014, Minerva anestesiologica.

[4]  A. Camm,et al.  Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. , 2014, Chest.

[5]  L. Friberg,et al.  Atrial fibrillation patients do not benefit from acetylsalicylic acid. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  P. Kirchhof,et al.  A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[7]  K. Tajiri,et al.  Liver physiology and liver diseases in the elderly. , 2013, World journal of gastroenterology.

[8]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[9]  B. Stambler.  A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin , 2013, International archives of medicine.

[10]  G. Lip,et al.  Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. , 2013, International journal of cardiology.

[11]  G. Lip,et al.  Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation , 2013, Thrombosis and Haemostasis.

[12]  R. Hoffman,et al.  Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  J. Collins,et al.  Reversal of Dabigatran with Haemodialysis in a Patient Requiring Decompression for Cord Compression from an Epidural Abscess , 2013, Nephrology.

[14]  M. O’Donnell,et al.  Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. , 2013, The Canadian journal of cardiology.

[15]  G. Lip,et al.  Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. , 2013, Journal of the American College of Cardiology.

[16]  K. Aonuma,et al.  The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation , 2013 .

[17]  A. Camm,et al.  European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[18]  S. Manzano-Fernández,et al.  Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? , 2013, Thrombosis and Haemostasis.

[19]  M. Ezekowitz,et al.  Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) , 2013, European heart journal.

[20]  P. Conley,et al.  A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa , 2013, Nature Medicine.

[21]  W. Dager,et al.  Removal of dabigatran by hemodialysis. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  G. Lip,et al.  General mechanisms of coagulation and targets of anticoagulants (Section I) , 2013, Thrombosis and Haemostasis.

[23]  T. Slowinski,et al.  Effective elimination of dabigatran by haemodialysis , 2013, Thrombosis and Haemostasis.

[24]  G. Lip,et al.  Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions? , 2013, Thrombosis and Haemostasis.

[25]  H. Leufkens,et al.  The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non‐valvular atrial fibrillation , 2013, Journal of thrombosis and haemostasis : JTH.

[26]  D. Saranath,et al.  Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response. , 2012, The Journal of the Association of Physicians of India.

[27]  G. Lip,et al.  Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation , 2012, Thrombosis and Haemostasis.

[28]  B. Norrving,et al.  Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor , 2012, Thrombosis and Haemostasis.

[29]  L. Køber,et al.  Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.

[30]  J. Cracowski,et al.  Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban , 2012, Thrombosis and Haemostasis.

[31]  J. Douketis,et al.  Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors , 2012, American journal of hematology.

[32]  G. Lip,et al.  Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice , 2012, Thrombosis and Haemostasis.

[33]  S. Yusuf,et al.  Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial , 2012, Circulation.

[34]  A. Banerjee,et al.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study , 2011, Thrombosis and Haemostasis.

[35]  J. Plumb,et al.  Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[36]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[37]  J. Tolstrup,et al.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study , 2011, Thrombosis and Haemostasis.

[38]  G. Lip,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[39]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[40]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[41]  Rajeev Chaudhry,et al.  Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. , 2009, Mayo Clinic proceedings.

[42]  R. Perera,et al.  Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review , 2008, Circulation. Cardiovascular quality and outcomes.

[43]  R. Beyth,et al.  Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[44]  S. Middleton,et al.  Barriers to the Use of Anticoagulation for Nonvalvular Atrial Fibrillation: A Representative Survey of Australian Family Physicians , 2008, Stroke.

[45]  K. Rathgen,et al.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.

[46]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[47]  B. Horne,et al.  Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study , 2006, Journal of Thrombosis and Thrombolysis.

[48]  J. Dwyer,et al.  Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices. , 2006, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[49]  S. Sacco,et al.  Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke: Results From a Population-Based Study , 2005, Stroke.

[50]  Mark Crowther,et al.  Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.

[51]  O Pelkonen,et al.  Age and cytochrome P450‐linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions , 1997, Clinical pharmacology and therapeutics.

[52]  Martin R Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[53]  D. Fernández de Velasco Pérez.  [Dabigatran versus warfarin in patients with mechanical heart valves]. , 2014, Revista clinica espanola.

[54]  G. Lip,et al.  Vitamin K antagonists in heart disease: Current status and perspectives (Section III) , 2013, Thrombosis and Haemostasis.

[55]  CardioPulse Articles: peripartum cardiomyopathy registry: a new ESC initiative. , 2013, European heart journal.

[56]  C. Samama,et al.  [Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013]. , 2013, Annales francaises d'anesthesie et de reanimation.

[57]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[58]  J. Stangier.  Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate , 2008, Clinical pharmacokinetics.